ORAL SDZ PSC 833 AND INTRAVENOUS PACLITAXEL IN ADVANCED CANCER

口服 SDZ PSC 833 和静脉注射紫杉醇治疗晚期癌症

• 批准号: 6274237
• 负责人: PAULA M. FRACASSO
• 金额: $ 2.24万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6274237
• 关键词: antineoplastics; clinical research; clinical trial phase I; combination chemotherapy; drug screening /evaluation; human subject; intravenous administration; multidrug resistance; neoplasm /cancer chemotherapy; oral administration; paclitaxel

The development of drug resistance to antineoplastic drugs is a tremendous obstacle to effective treatment of human malignancies. The problem of drug re-sistance is compounded by the emergence of tumors cross-resistant to multiple chemotherapeutic agents related in structure and function to the original selective agent. This phenomenon, termed multidrug resistance, may be caused by a protein, P-glycoprotein, which acts as an ATP-dependent efflux pump reducing the intracellular accumulation of certain antineoplastic agents.

抗肿瘤药物耐药性的产生是 有效治疗人类恶性肿瘤的巨大障碍。 这 肿瘤的出现加剧了耐药性问题 对结构相关的多种化疗药物具有交叉耐药性 并作用于原始选择剂。 这种现象，称为 多重耐药性可能是由一种蛋白质 P-糖蛋白引起的， 作为 ATP 依赖性外排泵，减少细胞内 某些抗肿瘤药物的蓄积。